ED, Evidence Generation Lead - ILD​/Lung

As an employee of Boehringer Ingelheim, you will actively contribute to the discovery, development and delivery of our products to our patients and customers. Our global presence provides opportunity for all employees to collaborate internationally, offering visibility and opportunity to directly contribute to the companies' success. We realize that our strength and competitive advantage lie with our people. We support our employees in a number of ways to foster a healthy working environment, meaningful work, mobility, networking and work-life balance.

Our competitive compensation and benefit programs reflect Boehringer Ingelheim's high regard for our employees.

The Executive Director, Evidence Generation Lead converts Therapeutic Area (TA)/ Asset medical strategy into a prioritized, US-specific evidence plan and carries that plan through from evidence gap identification and prioritization to execution tracking, handoff for dissemination and impact review. The role is the single named owner of US evidence accountability for the assigned asset, disease state or evidence-need grouping.

The incumbent translates medical strategy, field medical signal, stakeholder engagement insight, medical inquiry data, published and competitive evidence landscape, external expert input and identified guideline and payer evidence gap into a prioritized US integrated evidence plan (IEP). The incumbent resolves competing priorities, determines the recommended funding and execution route for each question, advances the plan through the applicable evidence governance forum, and secures delivery and capacity commitments from key stakeholders (e.g. HEOR and Value & Access, Global Epidemiology, Grants & Research, external investigators and research vendors).

The Evidence Generation Lead supports coordinated dissemination of generated evidence, ensuring dissemination strategy is aligned with prioritized evidence gaps, executed timely and is optimized.

The incumbent applies breadth across real-world evidence, interventional and non-interventional studies, externally sponsored and investigator-initiated research, as well as outcomes research to select appropriate pathways, engaging specialist methodological expertise as needed.

Evidence Gap Identification and Translation:

Translates TA/Asset medical strategy, field medical input, stakeholder engagement insight, medical inquiry data and evidence landscape review into a prioritized list of US evidence gaps expressed as answerable evidence questions.

Gathers and synthesizes evidence needs and knowledge gaps from Medical Affairs strategy, MSL teams, the Stakeholder Strategy Lead, medical inquiry and contact center data, and impact and analytics reporting; from systematic review of the published evidence and competitive evidence landscape; from external expert, advisory board and investigator input; from guideline, payer evidence gaps identified with HEOR and Value & Access; and from Global evidence plans and read-across from completed BI studies.

Maintains the US evidence gap list and re-baselines priorities annually against measured impact and new information.

Prioritization, Routing and Governance:

Resolves competing TA evidence priorities into one integrated US evidence plan aligned with the Integrated Evidence Plan (IEP).

Recommends the evidence generation approach and study type for each prioritized question, including funding and execution route across internal HEOR, Global Epidemiology, externally sponsored and investigator-initiated research through Grants & Research, and vendor-delivered real-world evidence.

Assesses feasibility before routing, including availability and fitness for purpose of candidate real-world data sources, methodological fit, indicative cost, timing and internal or external capacity, and documents the basis for the recommended approach.

Develops each prioritized question into a concept sufficient for a governance decision and partner handoff (i.e., objective, rationale, proposed approach, indicative cost and timing) and prepares the funding case for the recommended route.

Advances the integrated US evidence plan through the applicable evidence governance forum and represents US evidence priorities in that forum.

Secures delivery, capacity and timeline commitments from executing partners once priorities and routes are confirmed and escalates unresolved feasibility or capacity constraints.

The…